Idealp-Pharma launches « hit-to-candidate » services
Services to accelerate programs from biological target to first-in-man use Idealp-Pharma is launching fully integrated drug discovery and preclinical development services combining medicinal chemistry, cheminformatics,
screening, early ADMET and preclinical development capabilities to speed up
partner’s and client’s small molecules programs from biological target to firstin-
man use.
According to Serge Petit, PhD, President and CEO, “Being a one-stop-shop company adds significant value because the lead optimisation process involves iterative cycles for incremental optimization. The main advantages of our one-stop-shop service are to have access to all the experimental data, to be able to refocus the synthesis program and then to make the best decision for the lead optimisation process in accordance with our customers’ specifications.”
“Idealp-Pharma manages its customers’ hit discovery and validation, hit-to-lead
progression and lead-to-candidate process. Our aim is to deliver chemically and
biologically validated hits, accelerating lead optimization and identying IND candidate for our customers”, said Serge Petit. Idealp-Pharma supports also its client’s drug discovery activities by providing modular and customized services such as medicinal chemistry and cheminformatics studies.
More information about integrated drug discovery services can be found at www.idealp-pharma.com
About Idealp-Pharma
Idealp-Pharma’s aim is to expand partner’s drug pipeline by accelerating drug
discovery process from the biological target to first-in-man use. Idealp-Pharma
provides a range of flexible services: including fully integrated drug discovery and preclinical development, medicinal chemistry and cheminformatics.
Idealp-Pharma’s purpose-built lab covers a total of 2000 square meters. Idealp-Pharma now employs 60 staff. More information about Idealp-Pharma can be found at www.idealp-pharma.com
